Overview

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired renal function.
Phase:
N/A
Details
Lead Sponsor:
Fujian Akeylink Biotechnology Co., Ltd.